BRIEF-GSK files regulatory submission for variation to marketing authorisation for Ambrisentan
December 11, 2014 at 07:05 AM EST
* GSK press release: GSK announces EU regulatory submission seeking extended indication for Ambrisentan (Volibris) in pulmonary arterial hypertension
